Condition: The First Affiliated Hospital of Nanchang University · Sponsor: Shandong Cancer Hospital and Institute
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
This description comes directly from the study's public registry record.
zengjun Li · 13642138692 · zengjunli@163.com
Dan Liu · 13256139207
Always discuss trial participation with your own doctor first.
| The First Ailliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05933967